Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Anticancer Treatment × osimertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 19 Carcinoma 4 NSCLC 3 Lung Neoplasms 3 Neoplasm Metastasis 2 Stage IB-IIIA Non-small Cell Lung Carcinoma 1 Non-small Cell Carcinoma 1 Neoplasms 1 Neoplasm, Residual 1 NSCLC Patients With Brain Metastasis 1 Locally Advanced or Metastatic Non-squamous NSCLC 1 Locally Advanced or Metastatic EGFR T790M+ NSCLC 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1 Bronchial Neoplasms 1 Brain Neoplasms 1 Anticancer Treatment 1

Interventions

osimertinib 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02151981 2025-01-07

AURA3

AstraZeneca

Phase 3 Completed

421 enrolled 18 charts

Anticancer Treatment

Data powered by HemOnc (CC BY 4.0) Colophon ⚡